Ida-FLAG chemotherapy, which consists of fludarabine, high dose cytosine arabinoside, idarubucine, and G-CSF, is accepted as an efficient chemotherapeutical regimen in the refractory and/or relapsed AML, ALL, and relapsed malign lymphomas. In this report, the result of the patients who have recieved Ida-FLAG regimen in our center, have been evaluated retrospectively. Total 10 patients were included and mean age was 41.1±11.2 years. Seven of them were relapsed or refractory AML, 2 of them relapsed ALL and one patient was transformed low grade lymphoma. All of the patients had recieved multiple chemotherapy regimens before. All patients died bacaues of febrile neutropenia, hemorrhage and bone marrow failure. In the literature, Ida-FLAG results are better and the mortality is less. In our patients, the mortality was high, most probably because of very bad prognosis patient selection. With our results, it can be suggested that, Ida-FLAG is not a good choice in the selected patient group of relapsed-refractory, multiple chemotherapy administered patients
